Hemoperfusión con dispositivo CytoSorb en paciente con COVID-19

César Mercado Ferrer; Emilio Rey Vela; Jorge Rico Fontalvo; Rodrigo Daza Arnedo; Nehomar Pájaro Galvis; Greisy González; Jaime Gómez Ayala; Víctor Leal Martínez; Emilio Abuabara Franco; Alonso Pomares Lara; Christian Pérez Calvo; María Raad Sarabia

doi:10.22265/acnef.8.1.515

Hemoperfusión con dispositivo CytoSorb en paciente con COVID-19

Translated title of the contribution: Hemoperfusion with the Cytosorb device in a patient with severe COVID-19

César Mercado Ferrer, Emilio Rey Vela, Jorge Rico Fontalvo, Rodrigo Daza Arnedo, Nehomar Pájaro Galvis, Greisy González, Jaime Gómez Ayala, Víctor Leal Martínez, Emilio Abuabara Franco, Alonso Pomares Lara, Christian Pérez Calvo, María Raad Sarabia

Research output: Articles / Notes › Scientific Article › peer-review

Abstract

The COVID-19 disease is an infectious disease caused by the SARS-CoV 2 virus whose clinical presentation is very heterogeneous: it can range from asymptomatic people to critically ill patients, with cytokine storm, acute respiratory distress, organ dysfunction and even death. Current therapies for its treatment are aimed at reducing the impact of the inflammatory cascade, and within these we find hemoadsorption technologies such as the CytoSorb membrane. Next, we present a 31-year-old male patient, who consulted due to severe symptoms of COVID-19 and showed an evident clinical and biochemical improvement after using the CytoSorb device. This is the only documented patient in Colombia who has undergone haemoperfusion therapy with this device in conjunction with prolonged intermittent renal replacement therapy and favorable clinical outcomes have been recorded.

Translated title of the contribution	Hemoperfusion with the Cytosorb device in a patient with severe COVID-19
Original language	Spanish
Article number	e515
Journal	Revista Colombiana de Nefrologia
Volume	8
Issue number	1
DOIs	https://doi.org/10.22265/acnef.8.1.515
State	Published - 2021
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.22265/acnef.8.1.515

Cite this

Mercado Ferrer, C., Rey Vela, E., Rico Fontalvo, J., Daza Arnedo, R., Pájaro Galvis, N., González, G., Gómez Ayala, J., Leal Martínez, V., Abuabara Franco, E., Pomares Lara, A., Pérez Calvo, C., & Raad Sarabia, M. (2021). Hemoperfusión con dispositivo CytoSorb en paciente con COVID-19. Revista Colombiana de Nefrologia, 8(1), Article e515. https://doi.org/10.22265/acnef.8.1.515

@article{bcdf9339daed41e19b4783e51912cd3b,

title = "Hemoperfusi{\'o}n con dispositivo CytoSorb en paciente con COVID-19",

abstract = "The COVID-19 disease is an infectious disease caused by the SARS-CoV 2 virus whose clinical presentation is very heterogeneous: it can range from asymptomatic people to critically ill patients, with cytokine storm, acute respiratory distress, organ dysfunction and even death. Current therapies for its treatment are aimed at reducing the impact of the inflammatory cascade, and within these we find hemoadsorption technologies such as the CytoSorb membrane. Next, we present a 31-year-old male patient, who consulted due to severe symptoms of COVID-19 and showed an evident clinical and biochemical improvement after using the CytoSorb device. This is the only documented patient in Colombia who has undergone haemoperfusion therapy with this device in conjunction with prolonged intermittent renal replacement therapy and favorable clinical outcomes have been recorded.",

keywords = "Acute kidney injury, COVID-19, Hemoperfusion",

author = "{Mercado Ferrer}, C{\'e}sar and {Rey Vela}, Emilio and {Rico Fontalvo}, Jorge and {Daza Arnedo}, Rodrigo and {P{\'a}jaro Galvis}, Nehomar and Greisy Gonz{\'a}lez and {G{\'o}mez Ayala}, Jaime and {Leal Mart{\'i}nez}, V{\'i}ctor and {Abuabara Franco}, Emilio and {Pomares Lara}, Alonso and {P{\'e}rez Calvo}, Christian and {Raad Sarabia}, Mar{\'i}a",

year = "2021",

doi = "10.22265/acnef.8.1.515",

language = "Espa{\~n}ol",

volume = "8",

journal = "Revista Colombiana de Nefrologia",

issn = "2389-7708",

publisher = "Asociacion Colombiana de Nefrologia e Hipertension Arterial",

number = "1",

}

Mercado Ferrer, C, Rey Vela, E, Rico Fontalvo, J, Daza Arnedo, R, Pájaro Galvis, N, González, G, Gómez Ayala, J, Leal Martínez, V, Abuabara Franco, E, Pomares Lara, A, Pérez Calvo, C & Raad Sarabia, M 2021, 'Hemoperfusión con dispositivo CytoSorb en paciente con COVID-19', Revista Colombiana de Nefrologia, vol. 8, no. 1, e515. https://doi.org/10.22265/acnef.8.1.515

TY - JOUR

T1 - Hemoperfusión con dispositivo CytoSorb en paciente con COVID-19

AU - Mercado Ferrer, César

AU - Rey Vela, Emilio

AU - Rico Fontalvo, Jorge

AU - Daza Arnedo, Rodrigo

AU - Pájaro Galvis, Nehomar

AU - González, Greisy

AU - Gómez Ayala, Jaime

AU - Leal Martínez, Víctor

AU - Abuabara Franco, Emilio

AU - Pomares Lara, Alonso

AU - Pérez Calvo, Christian

AU - Raad Sarabia, María

PY - 2021

Y1 - 2021

N2 - The COVID-19 disease is an infectious disease caused by the SARS-CoV 2 virus whose clinical presentation is very heterogeneous: it can range from asymptomatic people to critically ill patients, with cytokine storm, acute respiratory distress, organ dysfunction and even death. Current therapies for its treatment are aimed at reducing the impact of the inflammatory cascade, and within these we find hemoadsorption technologies such as the CytoSorb membrane. Next, we present a 31-year-old male patient, who consulted due to severe symptoms of COVID-19 and showed an evident clinical and biochemical improvement after using the CytoSorb device. This is the only documented patient in Colombia who has undergone haemoperfusion therapy with this device in conjunction with prolonged intermittent renal replacement therapy and favorable clinical outcomes have been recorded.

AB - The COVID-19 disease is an infectious disease caused by the SARS-CoV 2 virus whose clinical presentation is very heterogeneous: it can range from asymptomatic people to critically ill patients, with cytokine storm, acute respiratory distress, organ dysfunction and even death. Current therapies for its treatment are aimed at reducing the impact of the inflammatory cascade, and within these we find hemoadsorption technologies such as the CytoSorb membrane. Next, we present a 31-year-old male patient, who consulted due to severe symptoms of COVID-19 and showed an evident clinical and biochemical improvement after using the CytoSorb device. This is the only documented patient in Colombia who has undergone haemoperfusion therapy with this device in conjunction with prolonged intermittent renal replacement therapy and favorable clinical outcomes have been recorded.

KW - Acute kidney injury

KW - COVID-19

KW - Hemoperfusion

UR - http://www.scopus.com/inward/record.url?scp=85124135220&partnerID=8YFLogxK

U2 - 10.22265/acnef.8.1.515

DO - 10.22265/acnef.8.1.515

M3 - Artículo Científico

AN - SCOPUS:85124135220

SN - 2389-7708

VL - 8

JO - Revista Colombiana de Nefrologia

JF - Revista Colombiana de Nefrologia

IS - 1

M1 - e515

ER -

Hemoperfusión con dispositivo CytoSorb en paciente con COVID-19

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this